Experimental drug cocktail takes on childhood brain cancers
NCT ID NCT07567469
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before and after surgery to remove their tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fianlimab and cemiplimab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a new treatment option for children and young adults with recurrent brain tumors that are hard to treat.
- What could go wrong
- This is an early-phase trial (phase 1/2) with a small number of participants. The drugs may cause side effects or not work for everyone. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA (HGG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.